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ABSTRACT
THE KINETICS OF DRUG DISSOLUTION IN POLYMERS
DURING HOT-MELT EXTRUSION

by
Huayang Fang
Extrusion has been a most important and widely used continuous process in polymer
processing for over one hundred and fifty years. However, it has only been recently
applied and adopted by the pharmaceutical industry to prepare solid oral dosage
formulations with increased bioavailability for the poorly-water soluble drugs and
controlled release characteristics for the water-soluble drugs. In pharmaceutical Hot-melt
extrusion poorly water soluble drug particulates are mixed with water soluble polymer
excipient particulates and fed in the extruder, where the polymer is melted, after which
the drug particulates begin to dissolve into the polymer melt. Extrusion-generated mixing
accelerates dissolution process. One issue concerning the pharmaceutical industry is the
degradation of drugs when they are exposed to relatively high temperatures of the
extrusion process (usually 100 ̊ C above ambient). In order to keep drugs from thermally
degrading and at the same time achieving complete dissolution, the dissolution kinetics of
drugs (APIs) must be specified for any given excipient/API pair, and a variety of
extrusion conditions. In this work the Brabender Batch Mixer is utilized to determine
such kinetic data at different concentrations and temperatures by connecting the
exponential torque decay after the introduction of the API to the API dissolution. The
time to complete the decay is then associated with the average residence time needed for
complete dissolution.
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CHAPTER 1
INTRODUCTION

1.1 Objective
Plastics Extrusion has been used in polymer processing for decades; However, it has only
been recently adopted by the pharmaceutical industry to prepare solid oral dosage
formulations with increased bioavailability for the poorly-water soluble drugs and
controlled release characteristics for the water-soluble drugs (Maniruzzaman, Boateng et
al. 2012). In the case of poorly water-soluble drugs, bioavailability enhancement is
achieved through amorphization of the crystalline drug, by dissolving it into watersoluble, hydrophilic polymers, thus forming what is known as a solid solution. Specific
intermolecular bonds with, and steric hindrance effects by the polymer chain prevent the
drug from re-crystallizing. Although the extrusion process during the production of solid
solutions typically takes place below the melting point of the drug, the potential of
thermal degradation of the API still exist and is in fact a major concern preventing the
universal applicability of the HME technique as a pharmaceutical manufacturing method.
To achieve total dissolution of the API in the formulation while minimizing its potential
thermal degradation, the dissolution kinetics of the API into the excipient must be known.
In this work, we determine the dissolution kinetics of a model API into a polymeric
excipient we by carrying out melt-mixing experiments using the Brabender Batch Mixer.

1

1.2 Background Information
1.2.1 Hot-melt Extrusion
Conventional extrusion was first invented for at the end of the eighteenth century ( James
et al., 2004). Since then, it has been used in the plastic, rubber, and food manufacturing

industry to produce stuffs such as pipes, sheets, and bags. Hot-Melt Extrusion has
emerged as a novel processing technology in developing molecular dispersions (solid
solutions) of poorly water-soluble active pharmaceutical ingredients (APIs) into various
hydrophilic polymer matrices. The Hot-melt extrusion technology has proven to be a
robust method of producing numerous drug delivery systems and therefore it has been
found to be useful in pharmaceutical industry as well (Andrews, 2010).(Crowley, 2007).
HME involves the compaction and conversion of blends from a powder or a granular mix
into a product of uniform shape (Breitenbach, 2002). During this process, polymer are
melted and formed into products having different shapes and sizes such as plastic tablets,
capsules, films, and implants for drug delivery. The extrusion process can be broken
down to the following general process sections ( Chokshi et al., 2004):
(1) Feeding of the extruder by hopper;
(2) Mixing, grinding, reducing the particle size, and kneading;
(3) Flow through the die;
(4) Extrusion from the die and further downstream processing.
Processing by HME can improve the bioavailability of the poorly water-soluble active
pharmaceutical ingredients by dissolving them into water-soluble polymers. At the same
time, oral dosages with controlled release characteristics can be produced by dispersing
water-soluble APIs into water-insoluble polymers. The elementary steps of this process
are identical to the ones involved in conventional plastics melt compounding by extrusion:
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(1) Feeding particulates; (2) melting; (3) dispersive and distributive mixing; (4)
devolatilization and stripping; (5) pressurization and pumping. However, for
pharmaceutical hot-melt extrusion, the API dissolution is an additional and very
important elementary step, along with melting of the polymeric excipient that precedes it,
and mixing which accelerates the dissolution process. In the case of solid solutions, the
drug’s (API) dissolution is an additional and very important elementary step, along with
melting of the polymeric excipient that precedes it, and mixing which accelerates the
dissolution process.
HME provides several advantages over traditional available pharmaceutical
processing techniques such as (1) Increased solubility and bioavailability of waterinsoluble compounds; (2) solvent free process; (3) economical process with reduced
production time, fewer processing steps, and a continuous operation; (4) capabilities of
sustained, modified, and targeted release; (5) better content uniformity in products; (6) no
needs for the compressibility of active ingredients; (7) uniform dispersion of fine
particles; (8) good stability at changing pH and moisture levels and safe application in
humans; (9) reduced number of unit operations and production of a wide range of
performance dosage forms; (10) a range of screw geometries (McGnity et al.,
2004).( Jones et al., 2008).(Grunhagen et al., 1995).(Singhal et al., 2011). However, the
HME also have disadvantages as well. The main drawbacks of HME include thermal
process (drug/polymer stability), use of high flow properties of polymers, and excipients
required and not suitable for relatively high heat sensitive molecules such as microbial
species and proteins (Grunhagen et al., 1995). (Singhal et al., 2011).
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As mentioned above, the thermal degradation of drugs (API) is one of the major
concern in pharmaceutical HME process. Producing an extrudate that contains a
molecularly disolved API and at the same time not overexposing the API to high
processing temperature for long time is one of the major objectives during the extrusion
of solid solutions. To achieve the balance between complete dissolution of API and
minimal thermal degradation of the API, the dissolution kinetics of the API particulates
inside the molten polymeric matrix during extrusion must be known. Melting of the
polymeric excipient, dispersive/distributive mixing, and API dissolution can occur
simultaneously during extrusion. Therefore to determine the dissolution kinetics of API,
the above phenomena must be isolated from each other. One way to achieving this is by
exploiting the effect of polymer melting, dispersion/ distribution of API particulates and
API dissolution on the melt viscosity of the polymer matrix: Melt viscosity decreases
with heat. Addition of particulates in molten polymers increases the melt viscosity.
Dissolution of an API into molten polymers generally decreases viscosity of virtue of
plasticization.
In this work we determine the dissolution kinetics of Acetaminophen into
Eudragit EPO by performing batch melt-mixing experiments using a specific addition
protocol: We first melt-mix the polymer and allow it to reach steady state, then add the
crystalline API quickly and in small quantities. In this way we minimize the effect of
dispersion and distribution that occurs prior to and during the dissolution of the API.
Following the addition of the API to the molten polymer, the dissolution kinetics are then
determined from the drop in the torque of the processed formulation by virtue of the API
plasticization of the polymer.
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1.3 Distributive Mixing and Dispersive Mixing
Generally, the mixing processes in single or twin screw extruders is induced by laminar
flow and is generally categorized into two types: dispersive mixing and distributive
mixing. Dispersive mixing refers to the process involving the particle size reduction of
particulate cohesive components such as fillers, polymer gels, or liquid droplets.
Distributive mixing refers to expanding and stretching the interfacial area between the
components lacking a cohesive force in between and distributing them uniformly
throughout the volume of the molten polymer. Dispersive mixing is mainly controlled by
the laminar shear or extensional forces and distributive mixing is mainly controlled only
by the flow-generated strains and does not require high stresses. According to the
definitions, the mixing of miscible liquids is regarded as distributive mixing, and mixing
of hard solid agglomerates, immiscible liquids, and soft agglomerates is regarded as
dispersive mixing (Tadmor, Gogos, 2006). The dispersive and distributive mixing of
solid agglomerates is schematically shown in Figure 1.1.
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Figure 1.1 Dispersive mixing and distributive mixing of solid agglomerates and
immiscible liquid droplets (Tasmor and Gogos, 2006).
Source: Z. Tadmor, C. G. Gogos (2006). Principles of Polymer Processing, John Wily & Sons, Inc.
Hoboken, NJ, USA.

1.4 Dissolution of API Particles in Polymeric Melt
The dissolution of API within the polymer largely depends on their physicochemical
properties. Good blended dispersions require miscibility between the drug and polymer
(Marsac, 2009). In practice, the majority of drug/polymer systems cannot fully miscibility,
they may likely to show only partial miscibility. This means that there exists a certain
thermodynamic solubility of drugs in polymer matrixes. HME can be carried out in two
distinctly different conditions, referred to here as Case I and Case II:
Case I: The processing temperature is above the melting temperature for a semicrystalline polymer, or the softening temperature for an amorphous polymer, (T g + 50 ~
100 ºC) but below the melting point of a drug.
Case II: The processing temperature is above both the melting temperature and the
softening temperature of semi-crystalline or amorphous polymers, respectively, and
above the melting point of a drug. It is important to be noted that processing temperature
should be the melt temperature instead of the set temperature of the processing equipment.
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It should also be noted that the glass transition temperature of an amorphous polymer or
the melting temperature of a semi-crystalline polymer may decreased if incorporation of
the API (Crowley et al., 2007).

Figure 1.2 Schematic representation of the morphological changes of the drug and
polymer system in the solution formation process for Case I.
Source: C.G. Gogos, H. Liu, P. Wang, in: Douroumis, “Hot-Melt Extrusion: Pharmaceutical
Applications,” Wiley: Chichester, UK, 2012.

Case I provides a viable method to circumvent the thermal degradation issues. In
Case I, the drug is processed below its melting point and mixed with a polymer melt, then
the solid drug particles gradually dissolve into the polymer excipient melt. And this
process should be able to provide a desirable polymer-drug solid dispersion or solid
solution. During the HME process, the solid API act as a solute and the polymeric melt
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act as a solvent. In addition, the dissolution rate and solubility of the API in the polymer
will increase with higher temperature.
The dissolution process of the drug in the polymer melt is schematically shown in
Figure 1.2. Firstly, the drug particles (black) and polymer particles (white) are fed into
the batch mixer or an extruder. Then, the polymer particles start melting due to the
conductive heat from the mixer or extruder barrel and frictional and plastic energy
dissipation. These two phenomena result in a process charge state that the solid drug
particles are suspended in a continuous polymer melt matrix. Then the polymer
molecules start to heat up the API particles and create a mass transfer boundary layer.
This layer shall be continuously wiped away and replaced with fresh polymer melt
nearby. The drug molecules diffuse into the polymer melt through the boundary layer,
and the size of the suspended drug particles will continue to decrease as the diffusion
goes. Finally, a homogeneous solution will be formed.
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Figure 1.3 Schematic representation of the morphological changes of the drug and
polymer system in the solution formation process for Case II.
Source: C.G. Gogos, H. Liu, P. Wang, in: Douroumis, “Hot-Melt Extrusion: Pharmaceutical
Applications,” Wiley: Chichester, UK, 2012

Case II, on the other hand, involves miscible or partially miscible liquid-liquid
mixing because both the polymer and drug will be melted. As shown in Figure 1.3, the
drug (black) and polymer (white) particles are fed into an extruder and processed by the
screw elements. Due to the heat transfer from the extruder barrel or a batch mixer, and
frictional and plastic dissipation, the polymer particles will melt first. During or after the
melting of the polymer, the drug particles will melt to droplets and be deformed by the
mixing flows generated by the screws. The droplets will be deformed along the shear
direction and blurred the contacting surface between the drug and polymer. As this
process goes on and with diffusion continuously being carried on, we will finally get a
homogeneous drug – polymer solution.
In both cases discussed above between either the dissolving API particles or the
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drug droplets and the molten polymer, the diffusion will happened. The “characteristic
diffusion time” t D is proportional to the square of the API phase droplet or ligament
radius L or the thin dimension D AB of a sheet Equation 1.1.

L2
tD =
DAB

(1.1)

During the HME process, the relationship between the rate of dissolution of drug
particles in molten polymer excipients, dm/dt, and the solubility, C S, is described by the
Noyes-Whitney as follows:
dm
dt

=

D×A×(Cs −C)

(1.2)

h×V

where m = mass (mol), t = time (s), C = concentration of solute dissolved at a particular
time (mol∙cm–3), CS = equilibrium solubility (mol∙cm–3), D = diffusivity (cm2∙s–1) , h =
apparent thickness (cm) of the aqueous boundary layer (depends on rate of stirring and
the temperature), and A = surface area available for dissolution (cm2).
The equation shows that the drug particle size and size distribution are very
important to the dissolution rate, since the total contacting surface area of the drug
particles will be changed accordingly. We can expect a higher dissolution rate if the
particle size gets smaller. Furthermore, the narrower the drug particle size distribution,
the more uniform the total dissolution time distribution needed for complete dissolution
of drugs in polymer melt will be (Liu, Gogos, 2012).
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In order to raise the dissolution rate, the surface area available have to be consider.
All of we know in extrusion process, the dispersive mixing may break up the drug
agglomerates or individual particles due to the high shear forces generated by the high
shear screw elements such as wide kneading blocks or Maddock elements (Tadmor,
Gogos, 2006). Then, the total contacting surface area of the drug particles to the
polymeric melt will be increased, thus the dissolution rate will increased. And the
distributive mixing can homogenize the drug concentration dissolved in the polymeric
melt, and leading more polymer melt into contact with the suspended drug particles. In
this way, both effects can raise or maintain the dissolution rate.
If the mixer set temperature increases, on the one hand, the diffusion coefficient
will increase due to the increased temperature and resultant decreased matrix viscosity;
on the other hand, Cs also will increase. Both of these factors will contribute to an
increase of the API dissolution rate in the molten polymer excipient. As the screw speed
increases, the distributive mixing is improved within the chamber as well, and thus a
higher concentration gradient around the drug particulates is available. Moreover, the
thickness of the mass transfer boundary layer decreases as the screw speed increases.
Both effects contribute to an increased dissolution rate.
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CHAPTER 2
MATERIALS AND METHORDS

2.1 Materials
Acetaminophen (APAP) (Spectrum Chemicals, Gardena, CA) was used as the model
crystalline API. APAP is a water-soluble BCS I drug with a T m of 169–170 ° C.
Acetaminophen consists of a benzene ring core, substituted by one hydroxyl group and
the nitrogen atom of an amide group in the para (1, 4) pattern. The amide group is
acetamide (ethanamide). It is an extensively conjugated system, as the lone pair on the
hydroxyl oxygen, the benzene pi cloud, the nitrogen lone pair, the p orbital on the
carbonyl carbon, and the lone pair on the carbonyl oxygen are all conjugated. The
presence of two activating groups also make the benzene ring highly reactive toward
electrophilic aromatic substitution. As the substituents are ortho, para-directing and para
with respect to each other, all positions on the ring are more or less equally activated. The
conjugation also greatly reduces the basicity of the oxygen and the nitrogen, while
making the hydroxyl acidic through delocalization of charge developed on the phenoxide
anion.
Eudragit® E is a copolymer composed of neutral methyl and butyl methacrylate,
and dimethylaminoethyl methacrylate repeating units. It has a T g ~45˚C. The molar ratio
of three monomers, methyl methacrylate, butyl methacrylate and dimethylaminoethyl
methacrylate, is 2:1:1 (Envonik, 2009). Two grades are available which have the same
chemical structure and molecular weight: one is Eudragit® E PO (E PO) in powder form;
the other is Eudragit® E 100 in granular form. This copolymer is soluble up to pH=5 and
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above this pH value is capable of swelling and becoming permeable to water. It is widely
used for masking unpleasant tastes and odors of drugs, protecting drugs against moisture,
and as a drug excipient for pharmaceutical applications.

2.2 Methods
2.2.1 Batch Mixer
A batch mixer is used to experimentally investigate the effects of extrusion process
parameters on the drug-polymer mixing. The batch mixer is a heated high-shear laminar
mixer, which has been extensively used in the plastics and rubber industry to simulate the
extrusion process or optimize the formulation. The laboratory scale batch mixer used
requires only 30-60 g of the material and many experiments can be performed in a short
period, thus making it an attractive choice for the HME study (Ghebre-Sellassie and
Martin, 2007). Furthermore, the screw speeds can be controlled separately without
altering the residence time in a batch mixer, which is difficult to realize if an extruder is
used.
All the runs were performed in a Brabender FE-2000 batch intensive mixer
utilizing counter-rotating screws, as illustrated in Figure 3.1. The batch mixer barrel is
heated electrically and cooled by air. The melt temperature sensor measures the actual
processed material temperature during melting and mixing; the torque meter can record
the resistance of material to the flow created by the counter-rotation of the screws.
Generally, about 70-75 vol. % fill degree of the chamber is recommended for good
mixing because the resulting “folding” of the free surfaces is beneficial to distributive
mixing. The free volume in the mixing chamber is 60 cc.
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(a)

(b)

Figure 2.1 The batch mixer (a) and roller screws (b) (Manufactured by Brabender Corp.)
Source: Liu, H. (May 2010). Hot Melt Mixing/Extrusion and Dissolution of Drug (Indomethacin) in
Acrylic Copolymer Matrices. Otto H. York Department of Chemical, Biological and Pharmaceutical
Engineering. Newark, New Jersey Institute of Technology. Ph.D Dissertation.
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Figure 2.2 The inside of the assembled Brabender batch mixer (without the front plate).
Source: Z. Tadmor, C.G. Gogos, “Principles of Polymer Processing,” Hoboken, NJ, USA, 2nd edition,
2006.

The Brabender batch mixer (Shown as Figures 2.1 and 2.2) was used for
compounding of the materials. All the experiment runs were performed in a Brabender
FE-2000 batch intensive mixer utilizing Ʃ-co-rotating screws, as illustrated in Figure 2.1.
During mixing the torque arising from the resistance of material to the flow created by
the counter-rotation of the screws, is recorded along with the melt temperature. The batch
mixer barrel is heated with electrical power and cooled down by air. All the materials
were mixed at 50 rpm for 20 min, while the set temperature of the mixer was 140°C. The
polymer will be processed for 10 minutes before we add the additive.
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CHAPTER 3
RESULTS AND DISCUSSION

3.1 Dispersion, Distribution, and Dissolution
To determine the characteristic constants that describe the dissolution kinetics of an API
in a molten polymeric excipient, we melt-mixed the API in the polymer matrix at
different concentrations and temperatures following the addition protocol mentioned in
Materials and Methods.

Figure 3.1 96%EPO-4%APAP vs. 100%EPO control.

Figure 3.1 compares the torque traces of pure EPO (control) and the sample
containing 96%EPO-4%APAP. From the control sample, it can be seen that EPO has
reached steady state at ~9 min. We can also see that the polymer remains stable for a
another 11 min, giving us a processing window of 20 min, in which we melt the polymer,
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allow it to reach steady state, then add the API, dissolve it, and finally allow the binary
formulation to reach steady state. From the torque tracer of the sample with the drug, we
can see that the formulation also remains stable for 10 min (after the addition of the API).
In the sample with 4% API, the torque fluctuation before the point of the maximum
torque after the addition of APAP, indicates the feeding surge, the wetting of the API
particles surface and their dispersion and distribution in the molten polymer matrix. The
final equilibrium torque is associated with the apparent viscosity of the dissolved
drug/polymer melt mixture in the mixing chamber.
The dispersion, distribution and dissolution of an API occur at the same time after
the addition of the API in the molten polymer. To minimize the effect of dispersion and
distribution of the API in the polymer matrix, we have kept the addition time and the
amount of API we are adding in the molten polymer to a minimum. The evolution of the
torque trace resulting from the addition of the API in the molten polymer can be used to
approximate the amount of the API dissolved while it is dispersed and distributed in the
molten polymer matrix. To do this we divide the torque trace into the following parts: 1-2
is the part beginning with the addition of the drug and ending at the maximum value of
torque recorded during after the drug is added. 2-3 is from the point where torque is
maximized until the drug fully dissolves. 3-4 is the steady state torque following the
dissolution of the drug (respective points on Figure 3.1). The following “cartoon
representation” of the evolving state of dispersive mixing and dissolution (Figure. 3.2) is
also used to help depict the phenomena occurring above:
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Figure 3.2 Cartoon representation of the dispersion, distribution and dissolution of APAP
in molten Soluplus.

For polymer matrices filled with particulate additives of dimensional aspect ratios near
unity, that is, nearly spherical, the rheological behavior at low volume fraction
concentrations φv < 10% resembles the shear thinning nature of the unfilled polymer
matrix, except that the viscosity is higher and increases with particulate concentration. In
other words, as expected from suspension theory, the suspended particulates do not
interact strongly and do not form a particulate network structure. Figure 3.3 plots the
steady state ratio of the viscosities of suspensions of spherical particles in Newtonian
liquids, µs, to the viscosity of Newtonian fluid, µf (blue data points). It was constructed
by Tomas using the data of a number of investigators. A variety of uniform-sized
particles having diameters of 1-400 µm were used. They included PS and polymethyl
methacrylate (PMMA) beads, rubber latex, and glass spheres. To avoid settling, either the
density of the suspending medium was adjusted or a medium of high viscosity was used.
The maximum packing density was determined by extrapolating a plot of 1/[(µs/µf)-1] vs.
φ to zero, giving φm = 0.625, very close to that of randomly packed spheres of equal size.
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Table 3.1 Suspension/fluid and Standard Error (SE)
APAP %

Suspension/fluid

SE

3

1.14

0.028359

4

1.16

0.009616

5

1.20

0.051369

10

1.52

0.048851

In Figure 3.3 we also plot the torque ratio (which is proportional to the viscosity of
the molten materials) of point 2 over point 1 (red data points, values in Table 3.1) for
different drug concentrations and compare these with the viscosity ratios of suspensions
from Tomas. It can be seen that for both data sets, the viscosity ratios for similar volume
fractions of added/suspended particles are very close. This is a strong indication that,
only a small portion of the added API has dissolved during the dispersion and distribution
of the API particles in the molten polymer matrix (between point 1 and 2). If a substantial
portion had dissolved, then the viscosity ratios for the API particles would be
significantly lower compared to these for non-dissolving particles, due to the
plasticization effect of the dissolved API on the polymer. Therefore we can safely assume
that the part of the curve corresponding to the dissolution of the API (points 2 to 3) is due
to the full amount the drug added in the molten polymer.
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Figure 3.3 Comparison of viscosity ratios of suspensions (Thomas et al) and viscosity
ratios of suspended drug particles in molten polymer matrix (this work).

3.2 Dissolution
3.2.1 Drugs Concentration Effect
Figure 3.5 shows the torque traces corresponding to the dissolution process of the API
into the molten polymer (points 2-4 in Figure 3.1) of formulations containing different
amount of APAP. Since the dissolution of a crystalline API is a physical reaction, it can
be described by rate laws governing chemical reactions. The differential rate law
describes how the rate of reaction varies with the concentration of various species, drugs
in this case, in the system. The rate of drugs dissolved is proportional to the rate of
change in concentrations of the drug, meaning, the rate is proportional to a derivative of a
concentration. The rate of the change either increases or decreases as time passes. In
exponential decay, the rate of change decreases over time - the rate of the decay becomes
slower with increasing time. Since the rate of change is not constant across the entire
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graph, these functions are not straight lines. Generally, there are three reaction orders,
such as zero order, first order, and second order. As Table 3.2 showing below:

Table 3.2 A Characteristic Plot of Rate Law
Reaction
Order

Differential Rate
Law

Integrated Rate
Law

Characteristic
Kinetic Plot

Slope of Kinetic
Plot

Zero

- d[A]/dt = k

[A]=[A]0 - kt

[A] vs. t

-k

First

- d[A]/dt = k[A]

[A]=[A]0 exp(-kt)

ln[A] vs. t

-k

Second

- d[A]/dt = k[A]^2

[A]=[A]0/(1+kt[A]0)

1/[A] vs. t

-k

In this work, we consider the rate in torque drop to be proportional to the rate of
dissolution of the API in the molten polymer, by virtue of the plasticization effect of the
API. We can, therefore, plot [A] vs. t, ln[A] vs. t, and 1/[A] vs. t to determine the reaction
rate order which the dissolution of the API corresponds to.
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Figure 3.4 The relationship of [A] vs.t, ln[A] vs.t, and 1/[A] vs.t.

Figure 3.4, shows the torque of 4% APAP plotted as [A], ln[A], and 1/[A] with
time t. From the trend lines corresponding the above plots, we see that the best
approximation to a straight line is obtained from a first order reaction (R 2= 0.7054),
where R2 is “The Plotting Fitted Values”: a statistical measure of how close the data are
to the fitted regression line.

Table 3.3 The Function of Dissolution Curve in Each Order.
Zero Order

y = 58.35 × t – 53.873, R2 = 0.0313

First Order

y = − 0.8797 × t – 0.7465, R2 = 0.7054

Second Order

y = − 0.1047 × t + 0.3827, R2 = 0.4992
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Because 0.7054 > 0.4992 > 0.0313, we consider the dissolution of APAP to be
characterized by first order reaction kinetics. That is:

𝐲 = 𝐍𝐞(−𝐤𝐭)

(3.0)

Figure 3.5 Torque decrease of the melt processed formulation during the dissolution of
various amount of APAP.

Figure 3.5 shows the torque decrease of the melt-processed formulation due to the
dissolution of different concentrations of APAP, curve fitted with the exponential decay
model, while Table 3.4 shows the calculated parameters of the exponential decay model
for the different concentrations of APAP. The torque drop evolution due to the
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dissolution and the resulting plasticization effect of the dissolved APAP on the melt
viscosity of Soluplus is consistent with the amount of drug added to the molten polymer:
For the highest concentration of API added (10%) the initial toque at which the
dissolution of the API begins, is highest compared to the lower concentrations due to the
higher volume fraction of suspended solid particles in the melt, as discussed above.
Additionally, the drop in torque for the highest concentration of drug is also the highest,
since it involves the largest fraction of the dissolving drug, which acts as a plasticizer for
the polymer melt.

Table 3.4 Exponential Decay Model Parameters

Concentration
N[Pre-exponential
Number]

3%

4%

5%

10%

1.01

1.48

1.79

3.41

k

2.01

3.31

2.83

2.53

0.93

0.98

0.97

0.97

R2

The physical meaning of the parameters of the exponential decay function are as
follows: (N) is the scaling factor of the decay function and corresponds to the value of the
y-axis (torque/viscosity) at t=0 (before any dissolution takes place). In our case (N)
corresponds to the highest value of torque, which is proportional to the amount of the
added API, following the addition, dispersion and distribution of the API in the polymer
melt, and the initiation of the API dissolution (point 2 in Figure 3.1). Plotting the value of
(N) vs. the initial concentration of APAP in the formulation yields a straight line, the
slope of which denotes the proportionality between the amounts of API added and the
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corresponding increase in the torque of the melt. (k) in the exponential decay function
indicates the decay rate of the material’s torque or viscosity due, in this case, to the
dissolution rate of the API. We consider this to be a constant with an average value of
2.46 ± 0.24, the relative standard error being within acceptable range (< 10%).

a
4
3.5

a = 0.3346*C + 0.0813
R² = 0.9971

3

(a)

2.5

2

a

1.5

Linear (a)

1
0.5
0

0

2

4

6

8

10

12

Initial APAP concentration

Figure 3.6 The relationship between N and Initial APAP Concentration.

Table 3.5 [k] Value Results at Different Concentrations of added particulate APAP with
Standard Deviation and Standard Error Values
Concentration
k

3
2.01

5
2.83

10
2.53

AV
2.46

SD
0.41

SE
0.24

The result obtained indicate that k is not a function of the initial concentration of the
added APAP.

3.2.2 Dissolution of the API at Different Processing Temperatures
To determine the relationship between dissolution of the API and processing temperature,
as well as the activation energy for dissolution, we carried out experiments at a fixed API
concentration (4%) at three different temperatures, namely, 130˚, 140˚ and 150˚C. We
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chose these three temperatures, because they are within the “HME Processing Window”
for the APAP/EPO system. Figure 3.7 shows the torque drop of the molten formulation
after the addition of 4% APAP at these three different temperatures.

Figure 3.7 Torque Decay Values due to the Dissolution of 4% APAP at 130˚C, 140˚C
and 150˚C.
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Table 3.6 Model Parameters in Different Temperature

Temperature(ºC)

130

140

150

N[Pre-exponential
Number]

2.81

1.48

0.87

k

3.99

3.31

4.31

0.99

0.98

0.99

R2

Table 3.6 lists the parameters determined from curve fitting of the exponential decay
model to the experimental data obtained at different temperatures.

a
3
2.5

a value

2
1.5

a

1

Linear (a)

a = -0.0972*T + 15.324
R² = 0.9553

0.5

0
125

130

135

140

145

150

155

Temperature

Figure 3.8 The relationship between N and Temperature.

According to the Arrhenius Equation, describing an “Arrhenius rate process” the k value
can be represented as follows:
lnk = lnk 0 −

Ea
RT
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(3.1)

1

The ln[k] is a function of [ T ], the slope of Equation 3.1(Slope =

dln [k]
d1

) equals

Ea
R

which R

T

refers gas constant and Ea can be defined as the minimum energy required to start a
reaction (Generally, Ea = f(T)). Table 3.7 lists the each ln[k] values corresponding to
different temperatures. The value of slope (

dln[k]
d1

=

Ea
R

) can be regard as a constant value

T

cause its Standard Error value is small enough (generally, less than 10% of Average
value). So the activation energy for APIs dissolution process in excipients is insensitive
for temperature [T] as present in Figure3.9.

1

Table 3.7 The relationship between ln[k] and T
T

130

140

150

AV

SD

SE

𝟏
𝐓

0.00248

0.00242

0.00236

ln[k]

1.38459

1.19804

1.46177

1.30

0.13

0.08

𝐄𝐚
𝐑

558.199

494.968

618.549

557.2

61.8

35.7

The value and units of the Gas Constant R is: 8.3145[J/mol.ºK]. Therefore, the Activation
Energy for Dissolution as measured by the viscosity decrease of the dissolving APAP in
EPO system is Ea = (557.2)(8.3145) = 4.6 [kJ/mol] and does not vary with temperature in
the range of 130 - 150ºC.
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1

Figure 3.9 The relationship between ln[k] and T.
Using these two parameters N and k evaluated through the torque time decay
results in the Brabender internal mixer, the exponential decay function can depict the
kinetics of drug’s dissolution in the APAP/EPO system in the API concentration range of
3 – 10% and in the Processing Temperature range of 130 - 150ºC. It was found that in
these ranges, neither the drag concentration, nor the processing temperature affect k. On
the other hand N (that is, the torque or system viscosity) is affected by both processing
temperature and added APAP particulates concentration. The first dependence is
Arrhenius in nature, and the second obeys the solid suspension viscosity-concentration
behavior. Combining Figure 3.6 and Figure 3.8, the N behavior can be depicted by the
function of concentration and temperature, shown in Equation 3.2 and Equation 3.3
below
N = 0.3346 × [𝐶] + 0.0813, R2 = 0.9971

(3.2)

N = −0.0972 × [𝑇] + 15.32, R2 = 0.9561

(3.3)
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Thus, keeping temperature constant and different concentration of drugs we can
use function Equation (3.4) to get its dissolution kinetics; conversely, for the same drug
concentration but different process temperature, Equation (3.5) can be used to determine
the time dependent dissolution y = Ne(−kt) , where the y value equals N when t = 0 and
when t = ∞ then N or y = 0.
y = N[0.3346 × C + 0.0813] × exp(−k × t)

(3.4)

y = N[−0.0972 × T + 15.324] × exp(−k × t)

(3.5)

The time required for the torque to reach a value equal to (N/𝐞𝟓 ) = 0.0067N (0.0165N)
can be considered safely to be the time needed for complete dissolution of the APAP in
EPO under given conditions in the experimental ranges used. And this time should be
given as a guide to the appropriate average residence time to be used for HME.
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CHAPTER 4
SUMMARY AND CONCLUSIONS

4.1 Summary
The NJIT/PPI research group studying pharmaceutical Hot Melt Extrusion, within which
the author of this thesis worked, considers this process to be a special case of reactive
polymer compounding, in which the particulate additive compounded dissolves during
compounding. In other words, the dissolution process represents the “reaction”, not a
chemical one but a physical one. In this work, we examined experimentally the process of
an API dissolving in polymer excipient with a focus of minimizing the effects of
dispersive and distributive mixing after the addition of the API particulates into the
molten EPO during batch mixing/processing in a Brabender mixer. In this way we were
able to follow the exponential decay in the Brabender torque and determine the
dissolution kinetics of the API, since it is the only physical process taking place after the
addition of the API. The torque reduction is entirely attributable to the dissolution of the
API, which acts as a plasticizer, reducing the polymer excipient viscosity.
Acetaminophen (APAP) and Eudragit® E PO (EPO) were chosen as the model API and
polymer. The experimental times required for the complete reduction of the torque under
different processing conditions are taken as the minimum required residence times during
Hot Melt Extrusion.
The analysis of the entirety of the experimental work conducted with APAP
dissolving in EPO under different process temperatures and at different APAP
concentrations, resulted in the specification of the two dissolution rates expressions,
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namely, Equation 3.3. and Equation 3.4. The dissolution of APIs in polymer excipients is
an exponential decay and characterized by two different decay function parameters, N
and k.
With the two rate expressions (Equations 3.3. and 3.4) and specific values of the
parameters for the APAP/EPO API/polymer excipient pair is possible for oral dosage
engineers and scientists to specify the Hot Melt Extrusion (HME) minimum residence
times, which will guarantee the complete dissolution of the API and at the same time
minimize the API degradation during HME. All this eliminates the need of conducting
costly and time-consuming HME experiments. Therefore, the work conducted in this
thesis represents a powerful methodology of specifying the HME process “operating
window” for any API/Polymer excipient pair.
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